Browsing Wolfson Institute of Preventive Medicine by Author "Callister, ME"
Now showing items 1-4 of 4
-
165 Can Pathway Navigation increase lung cancer screening uptake? Protocol for a nested randomised controlled trial and process evaluation
McInnerney, D; Simmonds, I; Hancock, N; Rogerson, S; Lindop, J; Gabe, R; Vulkan, D; Marshall, C; Crosbie, PA; Callister, ME (Elsevier, 2024-04-17) -
European position statement on lung cancer screening.
Oudkerk, M; Devaraj, A; Vliegenthart, R; Henzler, T; Prosch, H; Heussel, CP; Bastarrika, G; Sverzellati, N; Mascalchi, M; Delorme, S (2017-12)Lung cancer screening with low-dose CT can save lives. This European Union (EU) position statement presents the available evidence and the major issues that need to be addressed to ensure the successful implementation of ... -
The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials
Li, M; Zhang, L; Charvat, H; Callister, ME; Sasieni, P; Christodoulou, E; Kaaks, R; Johansson, M; Carvalho, AL; Vaccarella, S (Wiley, 2022-06-15)We aimed to explore the underlying reasons that estimates of overdiagnosis vary across and within low-dose computed tomography (LDCT) lung cancer screening trials. We conducted a systematic review to identify estimates of ... -
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial.
Murray, RL; Alexandris, P; Baldwin, D; Brain, K; Britton, J; Crosbie, PAJ; Gabe, R; Lewis, S; Parrott, S; Quaife, SL (2024-04)BACKGROUND: Up to 50% of those attending for low-dose computed tomography screening for lung cancer continue to smoke and co-delivery of smoking cessation services alongside screening may maximise clinical benefit. Here ...